How Biotechs Are Using Digital Twins for Clinical Trials

Episode 11 of Biotech Business with Fexingo explores how biotech startups are using 'digital twins' — AI-powered virtual patients — to simulate clinical trials, reduce costs, and accelerate drug development. Lucas and Luna break down the case of a mid-stage startup using digital twins to cut a Phase II trial's patient enrollment by 40 percent, saving an estimated $15 million and shaving eight months off the timeline. They discuss the technology behind it: generative models trained on historical trial data, real-world electronic health records, and synthetic control arms. They also tackle the skepticism from regulators and traditional clinicians, the risk of algorithmic bias when digital twins don't represent diverse populations, and why the FDA is cautiously opening the door to in silico evidence. Specific numbers, real trade-offs, and no hype. #DigitalTwins #ClinicalTrials #AIinBiotech #DrugDevelopment #SyntheticControlArms #FDA #InSilico #PhaseII #BiotechStartup #GenerativeModels #RealWorldData #PrecisionMedicine #AlgorithmicBias #LifeSciences #Business #Technology #FexingoBusiness #BusinessPodcast Keep every episode free: buymeacoffee.com/fexingo